Clinical Trial Detail

NCT ID NCT02096354
Title A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors EpicentRx, Inc.
Indications

colon adenocarcinoma

rectum adenocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.